AU2021107491A4 - Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCl from sustained release pellets formulations - Google Patents
Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCl from sustained release pellets formulations Download PDFInfo
- Publication number
- AU2021107491A4 AU2021107491A4 AU2021107491A AU2021107491A AU2021107491A4 AU 2021107491 A4 AU2021107491 A4 AU 2021107491A4 AU 2021107491 A AU2021107491 A AU 2021107491A AU 2021107491 A AU2021107491 A AU 2021107491A AU 2021107491 A4 AU2021107491 A4 AU 2021107491A4
- Authority
- AU
- Australia
- Prior art keywords
- methanol
- visible spectrophotometer
- make
- novel
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 229960003712 propranolol Drugs 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 238000009472 formulation Methods 0.000 title claims abstract description 10
- 238000013268 sustained release Methods 0.000 title claims abstract description 7
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 7
- 238000001514 detection method Methods 0.000 title claims abstract description 6
- 239000008188 pellet Substances 0.000 title claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000002835 absorbance Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 4
- 239000012488 sample solution Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 abstract 2
- 239000012085 test solution Substances 0.000 abstract 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 8
- 229960000607 ziprasidone Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 4
- 239000003405 delayed action preparation Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
NOVEL UV-VISIBLE SPECTROPHOTOMETER METHODS FOR DETECTION OF
PROPRANOLOL HCL FROM SUSTAINED RELEASE PELLETS FORMULATIONS
5 This invention relates to Novel UV-Visible Spectrophotometer methods for detection
of Propranolol HCI from sustained release pellets formulations wherein taking 40 mg
of Propranolol HCI RS in 100 ml of volumetric flask and dissolve and make the
volume with Methanol. Now take 5 ml of above solution & make up to 50 ml with the
Methanol. For Test solution; taking powder equiv. to 40 mg of Propranolol HCI in
0 100 ml volumetric flask and dissolve and make up to the volume with Methanol.
Now take 5 ml of above solution & make up to 50 ml with the Methanol; wherein
measuring the Absorbance of both Standard & Sample Solutions at 290 nm by UV
Visible Spectrophotometer.
5
20
25 8
Description
Title of the Invention
Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCI
from sustained release pellets formulations
Field of the Invention
This invention relates to Novel UV-Visible Spectrophotometer methods for detection
of Propranolol HCI from sustained release pellets formulations
Background of the Invention
CN108024966A FORMULATION HAVING CONTROLLED, DELAYED ACTIVE
INGREDIENT RELEASE relates to new pharmaceutical formulations that have
controlled, delayed active-ingredient release, and to a method for producing such
formulations. The invention further relates to theuse of these new galenic dosage
forms as drugs for treating diseases that require a delayed release of the active
ingredient, such as hypertension, or asthmatic diseases.
US2004091528A1 Soluble drug extended release system relates to novel oral
sustained-release formulations for delivery of an active agent (e.g., a drug),
especially a highly water soluble drug. More particularly, this invention relates to
novel formulations comprising a micelle-forming drug having a charge and at least
one polymer having an opposite charge. Methods of using the novel formulations are
also provided.
CN107714669A Ziprasidone controlled release preparation and preparation method
thereof discloses a ziprasidone controlled release preparation and a preparation
method thereof. The ziprasidone controlled release preparation is prepared from
ziprasidone, a framework materialand pharmaceutically acceptable auxiliary
materials, wherein a weight ratio of the ziprasidone to the framework material is 1 to
(1 to 6). The ziprasidone disclosed by the invention has a better controlled release
effect, so that drug administration times of patients are reduced, medication
compliance of the patients is improved, the maximum plasma concentration is
reduced, and the possibility ofQTc interval prolongation, caused by taking the
ziprasidone, of the patients is reduced. The preparation method of the ziprasidone
disclosed by the invention has the advantages of convenience in operation, safety,
controllability, higher yield and suitability for industrial production.
None of the cited references above disclose or teach what the present invention
discloses or teaches. The present invention distinguishable over these cited prior art
references.
Assay: By UV-Visible Spectrophotometer
Standard preparation:
Take 40 mg of Propranolol HCI RS in 100 ml of volumetric flask and dissolve and
make the volume with Methanol. Now take 5 ml of above solution & make up to 50
ml with the Methanol.
Test preparation:
Take powder equiv. to 40 mg of Propranolol HCI in 100 ml volumetric flask and
dissolve and make up to the volume with Methanol. Now take 5 ml of above solution
& make up to 50 ml with the Methanol.
Measure the Absorbance of both Standard & Sample Solutions at 290 nm by UV
Visible Spectrophotometer
Calculation:
Propranolol HCI:
AT x WS x 5 x 100 x 50 x Purity. = % of Assay
AS x 100 x 50 x WT x 5
Where
AT = Absorbance of test
AS = Absorbance of standard
WS = weight of standard
WT = weight of test
The detailed description of various exemplary embodiments of the disclosure is
described herein with reference to the accompanying drawings. It should be noted
that the embodiments are described herein in such details as to clearly communicate
the disclosure. However, the amount of details provided herein is not intended to
limit the anticipated variations of embodiments; on the contrary, the intention is to
cover all modifications, equivalents, and alternatives falling within the scope of the
present disclosure as defined by the appended claims.
It is also to be understood that various arrangements may be devised that, although
not explicitly described or shown herein, embody the principles of the present
disclosure. Moreover, all statements herein reciting principles, aspects, and embodiments of the present disclosure, as well as specific examples, are intended to encompass equivalents thereof.
The terminology used herein is for the purpose of describing particular embodiments
only and is not intended to be limiting of example embodiments. As used herein, the
singular forms "a"," "an" and "the" are intended to include the plural forms as well,
unless the context clearly indicates otherwise. It will be further understood that the
terms "comprises," "comprising," "includes" and/or "including," when used herein,
specify the presence of stated features, integers, steps, operations, elements and/or
components, but do not preclude the presence or addition of one or more other
features, integers, steps, operations, elements, components and/or groups thereof.
It should also be noted that in some alternative implementations, the functions/acts
noted may occur out of the order noted in the figures. For example, two figures
shown in succession may, in fact, be executed concurrently or may sometimes be
executed in the reverse order, depending upon the functionality/acts involved.
In addition, the descriptions of "first", "second", "third", and the like in the present
invention are used for the purpose of description only, and are not to be construed
as indicating or implying their relative importance or implicitly indicating the number
of technical features indicated. Thus, features defining "first" and "second" may
include at least one of the features, either explicitly or implicitly.
Unless otherwise defined, all terms (including technical and scientific terms) used
herein have the same meaning as commonly understood by one of ordinary skill in
the art to which example embodiments belong. It will be further understood that
terms, e.g., those defined in commonly used dictionaries, should be interpreted as
having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
These and other advantages of the present subject matter would be described in
greater detail with reference to the following figures. It should be noted that the
description merely illustrates the principles of the present subject matter. It will thus
be appreciated that those skilled in the art will be able to devise various
arrangements that, although not explicitly described herein, embody the principles of
the present subject matter and are included within its scope.
Assay:
By UV-Visible Spectrophotometer
Standard preparation:
Take 40 mg of Propranolol HCIRS in 100 ml of volumetric flask and dissolve and
make the volume with Methanol. Now take 5 ml of above solution & make up to 50
ml with the Methanol.
Test preparation:
Take powder equiv. to 40 mg of Propranolol HCI in 100 ml volumetric flask and
dissolve and make up to the volume with Methanol. Now take 5 ml of above solution
& make up to 50 ml with the Methanol.
Measure the Absorbance of both Standard & Sample Solutions at 290 nm by UV
Visible Spectrophotometer
Calculation:
Propranolol HCI:
AT x WS x 5 x 100 x 50 x Purity. = % of Assay
AS x 100 x 50 x WT x 5
Where
AT = Absorbance of test
AS = Absorbance of standard
WS = weight of standard
WT = weight of test
Claims (4)
1. Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCI
from sustained release pellets formulations.
2. The method as claimed in claim 1, wherein taking 40 mg of Propranolol HCI RS
in 100 ml of volumetric flask and dissolve and make the volume with Methanol. Now
take 5 ml of above solution &make up to 50 ml with the Methanol.
3. The method as claimed in claim 1, wherein taking powder equiv. to 40 mg of
Propranolol HCI in 100 ml volumetric flask and dissolve and make up to the volume
with Methanol. Now take 5 ml of above solution & make up to 50 ml with the
Methanol.
4. The method as claimed in claim 1, wherein measuring the Absorbance of both
Standard & Sample Solutions at 290 nm by UV-Visible Spectrophotometer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021107491A AU2021107491A4 (en) | 2021-08-25 | 2021-08-25 | Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCl from sustained release pellets formulations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021107491A AU2021107491A4 (en) | 2021-08-25 | 2021-08-25 | Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCl from sustained release pellets formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021107491A4 true AU2021107491A4 (en) | 2021-12-23 |
Family
ID=78958218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021107491A Ceased AU2021107491A4 (en) | 2021-08-25 | 2021-08-25 | Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCl from sustained release pellets formulations |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021107491A4 (en) |
-
2021
- 2021-08-25 AU AU2021107491A patent/AU2021107491A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abed et al. | Formulation and optimization of orodispersible tablets of diazepam | |
| EP3791867A1 (en) | Medicament-containing hollow particle | |
| CN103610650A (en) | Isosorbide mononitrate sustained-release pallets, preparation prepared from same and preparation method for isosorbide mononitrate sustained-release pallets | |
| Shin et al. | Formulation and in vivo pharmacokinetic evaluation of ethyl cellulose-coated sustained release multiple-unit system of tacrolimus | |
| AU2021107491A4 (en) | Novel UV-Visible Spectrophotometer methods for detection of Propranolol HCl from sustained release pellets formulations | |
| WO2007056125A2 (en) | Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances | |
| EP3646867A1 (en) | Pharmaceutical composition | |
| JPWO2012036078A1 (en) | Drug-containing film-coated particles with unpleasant taste masked | |
| Rahul et al. | A review on immediate release drug delivery systems | |
| US8778417B2 (en) | Anti-tumor plant-medicament sustained-release tablet of elemene | |
| Han et al. | Preparation, optimization and in vitro–in vivo investigation for capsules of the choline salt of febuxostat | |
| CN104367557A (en) | Preparation method of amorphous composition composed of drug active component and PVP | |
| Bodhe et al. | Formulation, development and evaluation of carbamazepine extended release tablet: dissolution apparatus USP IV | |
| EP2925320B1 (en) | Novel method for improving the bioavailability of low aqueous solubility drugs | |
| Tamkhane et al. | Design and Development of Prulifloxacin Formulations by Co-Crystallization Technique | |
| CN101095666B (en) | Novel hydrochloric acid tramadol sustained-release tablet and preparation method | |
| KR101739818B1 (en) | Pharmaceutical composition for oral administration in form of suspension comprising revaprazan or its salt | |
| WO2012023145A2 (en) | Prasugrel hydrochloride crystalline particles | |
| TWI746418B (en) | Pharmaceutical dosage forms comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate | |
| JP2012072133A (en) | Small-sized sustained release formulation of ambroxol hydrochloride | |
| CA2632198C (en) | Pharmaceutical formulation containing phenytoin sodium and magnesium stearate | |
| Mohanty et al. | Formulation and evaluation of losartan potassium sustained release tablets | |
| Khattak et al. | Comparative Bioavailability Assessment of Newly Developed Flurbiprofen Matrix Tablets and Froben SR® Tablets in Healthy Pakistani Volunteers | |
| Alshehri | Versatility of hot-melt extrusion for dosage form design | |
| US20190209551A1 (en) | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |